RxDoctor Payments Data

David Lim, MD

Cardiovascular Disease · Stockton, CANPI 1023050937

Payments from drug & device makers

$44,051in general payments, 2019–2025

Across 32 payments — averaging $1376.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ancora Heart, Inc.$42K
  • Boston Scientific$651
  • Medtronic$508
  • Merck$178
  • Boehringer Ingelheim$125
  • Baxter Healthcare$105
  • plus $334 from 10 others

What the payments were for

  • Consulting fees$42,15096%
  • Travel & lodging$8302%
  • Food & beverage$1,0712%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,051 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$673,583
Medicare patients
875
Services billed
7,110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban419$493,450
XareltoRivaroxaban190$236,753
EntrestoSacubitril/Valsartan159$181,429
JardianceEmpagliflozin67$76,758
Repatha SureclickEvolocumab47$35,120
FarxigaDapagliflozin Propanediol20$18,732
Atorvastatin Calcium921$11,354
Ezetimibe336$10,887
Repatha SyringeEvolocumab13$10,226
Praluent PenAlirocumab18$10,040
NexletolBempedoic Acid18$8,686
Rosuvastatin Calcium373$8,567
Metoprolol Succinate418$7,483
Losartan Potassium402$4,416
Carvedilol357$4,280

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$493,450419 claims
Johnson & JohnsonXarelto$15$236,753190 claims
Boehringer IngelheimJardiance$125$76,75867 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Stockton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →